CHRISTINE SHANK: Open Payments
NPI 1093290041 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$932 in 30 payments from 11 companies in 2025. Trend: 2023 $226 · 2024 $699 · 2025 $932
Food & beverage: $932
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $250 |
| Optinose US, Inc. | 3 | $155 |
| Regeneron Healthcare Solutions, Inc. | 5 | $129 |
| ABBVIE INC. | 2 | $105 |
| Neurocrine BioSciences, Inc. | 1 | $74 |
| GlaxoSmithKline, LLC. | 1 | $60 |
| Smith+Nephew, Inc. | 1 | $59 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Amgen Inc. | 1 | $16 |
Products named: DUPIXENT, Xhance, QULIPTA, INGREZZA, NUCALA, TULA, INSPIRE, Optimizer.
Industry payments across NE — which companies pay providers there.
